Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,144.6
5.8 (0.19%)

 

  • STI Straits Times Index
    3,144.6
    5.8 (0.19%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,514.6
    -
    Index delayed 15 minutes
  • HSI Hang Seng Index
    25,086.4
    -
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,381.2
    -
    Index delayed 15 minutes
  • N225 Nikkei 225
    27,739.9
    -230.3 (-0.82%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,097.0
    -
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 0.7M
  • Value: 4.9M
  • Rise: -
  • Fall: -
  • Unch: 761

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Metal Component0.059+0.002
MM2 Asia0.073+0.006
CapAllianz0.004+0.001
Olam Intl1.280-0.060
Shen Yao0.006-
HPH Trust USD0.225-
KTL Global^0.124+0.002
Serial System0.145+0.009
GSS Energy0.067-
Jiutian Chemical0.084-

World Indices

World Indices
Name Last Change
Nasdaq 14,660.6 -180.1
HSI 25,086.4
HSCEI 8,879.6
Jakarta 6,097.0
Nikkei 225 27,718.2 -252.1
SSE Comp 3,381.2
Shanghai A 3,543.7
Shanghai B 256.9
KOSPI 3,237.3 +4.7

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

ANNOVIS BIO INC ANNOVIS BIO INC
Updated on 27 Jul 2021 (End of trading day)
Last (USD): 112.240 Change: -2.270 High: 117.640 Remarks: -
Change (%): -1.98 Low: 105.030
Open 114.000 Yesterday's Close 114.50999999999999
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 542,161 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (USD) a -0.68729 Trailing EPS (USD) e -1.03433 NAV (USD) b 0.5497
PE a - Trailing PE f - Price / NAV b 204.1841
Dividend (USD) d - Cash In Hand (USD) g 0.7050 Issued & Paid-up Shares c 7,947,270
Dividend Yield (%) d - Price / Cash In Hand g 159.206 Treasury Shares h -
Market Cap (M) 892.002 Enterprise Value (M) 886.399
Piotroski F Score 2 Exchange Code ANVS Par Value ( $ ) n.a.
52 Weeks Volatility (%) 138.48 Free Float (%) 64.7
Sector & Industry Health Technology - Pharmaceuticals: Major
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 24 May 2021.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 27 Jan 2020.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference ANNOVIS BIO INC NYSE American 892.002 - - 204.1841 -
Industry Pharmaceuticals: Major NYSE American 500.064 - - 231.3453 -
Local Peer BROOKLYN IMMUNO THERAPEUTICS INC NYSE American 1,226.364 - - -277.2251 -
Local Peer NAVIDEA BIOPHARMACEUTICALS INC NYSE American 278.996 - - 14.8404 -
Local Peer AGEX THERAPEUTICS INC NYSE American 50.264 - - -8.2916 -
Local Peer TIMBER PHARMACEUTICALS INC NYSE American 34.489 - - -18.3549 -
Global Peer JOHNSON & JOHNSON NYSE 452,602.458 30.760 25.474 - 2.315
Global Peer PFIZER INC NYSE 235,662.749 24.507 21.248 3.4343 3.614
Global Peer ELI LILLY AND COMPANY NYSE 233,244.713 37.658 38.284 33.8102 1.214
Global Peer NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) NYSE 221,434.843 27.270 24.620 4.0975 2.119
Global Peer ABBVIE INC NYSE 208,043.054 45.664 40.921 15.1746 4.106
Global Peer MERCK & CO INC NYSE 195,576.314 27.675 27.828 7.2584 3.208
Global Peer ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS NASDAQ 175,948.482 54.628 43.938 12.1932 2.044
Global Peer NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS B DKK1 NYSE 158,236.431 24.556 23.538 17.1176 1.507
Global Peer BRISTOL-MYERS SQUIBB CO NYSE 150,767.936 - - 4.0092 2.739
Global Peer SANOFI SPON ADR ECH REP 0.5 ORD SHS NASDAQ 130,188.659 9.274 9.274 1.6889 2.596
Other Global Peers GLAXOSMITHKLINE ADR EACH CNV INTO 2 ORD GBP0.25 (NYSE), WUXI APPTEC (HKEx), TAKEDA PHARMACEUTICAL CO LTD SPON ADS EACH REP 0.5 ORD SHS (NYSE), ROYALTY PHARMA PLC (NASDAQ), HANSOH PHARMA (HKEx), VIATRIS INC (NASDAQ), INNOVENT BIO (HKEx), CANSINOBIO-B (HKEx), REPLIGEN CORP (NASDAQ), CUREVAC NV (NASDAQ), SINOPHARM (HKEx), BIOHAVEN PHARMACEUTICAL HLDG CO LTD (NYSE), ORGANON & CO (NYSE), HUTCHMED (HKEx), HUTCHMED (CHINA) LIMITED SPON ADS EACH REPR 5 ORD SHS (NASDAQ), LEGEND BIOTECH CORP SPON ADS EACH REP 2 ORD SHS (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), SH PHARMA (HKEx), JUNSHI BIO (HKEx), HYGEIA HEALTH (HKEx), REMEGEN-B (HKEx), APELLIS PHARMACEUTICALS INC (NASDAQ), CMS (HKEx), AKESO-B (HKEx), I MAB SPON ADS EACH REP 2.3 ORD SHS (NASDAQ), INNOCARE-B (HKEx), REATA PHARMACEUTICALS INC (NASDAQ), BAIYUNSHAN PH (HKEx), ALLAKOS INC (NASDAQ), IMMUNITYBIO INC (NASDAQ), SPRINGWORKS THERAPEUTICS INC (NASDAQ), GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 (NASDAQ), CEREVEL THERAPEUTICS HLDGS INC (NASDAQ), CHINARES PHARMA (HKEx), EMERGENT BIOSOLUTIONS INC (NYSE), KARUNA THERAPEUTICS INC (NASDAQ), SIMCERE PHARMA (HKEx), TURNING POINT THERAPEUTICS INC (NASDAQ), TRAD CHI MED (HKEx), NEKTAR THERAPEUTICS (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), CHINAGRANDPHARM (HKEx), IGM BIOSCIENCES INC (NASDAQ), ATAI LIFE SCIENCES NV (NASDAQ), OPKO HEALTH INC (NASDAQ), CSTONE PHARMA-B (HKEx), EVEREST MED-B (HKEx), HENLIUS (HKEx), ERASCA INC (NASDAQ), ATEA PHARMACEUTICALS INC (NASDAQ), QUANTERIX CORPORATION (NASDAQ), CARSGEN-B (HKEx), CENTESSA PHARMACEUTICALS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), SSY GROUP (HKEx), HEPALINK (HKEx), OCUMENSION-B (HKEx), ADC THERAPEUTICS SA (NYSE), ZYMEWORKS INC (NYSE), HARMONY BIOSCIENCES HLDGS INC (NASDAQ), AMNEAL PHARMACEUTICALS INC (NYSE), Y-MABS THERAPEUTICS INC (NASDAQ), CONNECT BIOPHARMA HLDGS LTD ADS EACH REP ONE ORD SHARE (NASDAQ), DAY ONE BIOPHARMACEUTICALS INC (NASDAQ), NURIX THERAPEUTICS INC (NASDAQ), KRYSTAL BIOTECH INC (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), UNITED LAB (HKEx), ANTENGENE-B (HKEx), Kimia Farma Tbk. (IDX), REPARE THERAPEUTICS INC (NASDAQ), TONGRENTANGCM (HKEx), ARCUTIS BIOTHERAPEUTICS INC (NASDAQ), KRONOS BIO INC (NASDAQ), GENERATION BIO CO (NASDAQ), IMMUNOTECH-B (HKEx), FORMA THERAPEUTICS HLDGS INC (NASDAQ), SILVERBACK THERAPEUTICS INC (NASDAQ), CULLINAN ONCOLOGY INC (NASDAQ), PETIQ INC (NASDAQ), MIND MEDICINE (MINDMED) INC (NASDAQ), SCICLONE PHARMA (HKEx), CKLIFE SCIENCES (HKEx), PHIBRO ANIMAL HEALTH CORP (NASDAQ), PHATHOM PHARMACEUTICALS INC (NASDAQ), KINIKSA PHARMACEUTICALS LTD (NASDAQ), NRX PHARMACEUTICALS INC (NASDAQ), ESSA PHARMA INC (NASDAQ), KINNATE BIOPHARMA INC (NASDAQ), OLEMA PHARMACEUTICALS INC (NASDAQ), KEROS THERAPEUTICS INC (NASDAQ), IDEAYA BIOSCIENCES INC (NASDAQ), OCULAR THERAPEUTIX INC (NASDAQ), ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ), GH RESEARCH PLC (NASDAQ), POINT BIOPHARMA GLOBAL INC (NASDAQ), SUTRO BIOPHARMA INC (NASDAQ), SHINEWAY PHARM (HKEx), ANNEXON INC (NASDAQ), AKERO THERAPEUTICS INC (NASDAQ), CALLIDITAS THERAPEUTICS AB SPON ADS EACH REP 2 ORD SHS (NASDAQ), G1 THERAPEUTICS IN (NASDAQ), ADAGENE INC SPON ADS EACH REP 1.25 ORD SHS (NASDAQ), PRAXIS PRECISION MEDICINES INC (NASDAQ), CRINETICS PHARMACEUTICALS INC (NASDAQ), ALIGOS THERAPEUTICS INC (NASDAQ), ACUMEN PHARMACEUTICALS INC (NASDAQ), ORIC PHARMACEUTICALS INC (NASDAQ), ZHAOKE OPHTH-B (HKEx), EVOLUS INC (NASDAQ), GOSSAMER BIO INC (NASDAQ), TALARIS THERAPEUTICS INC (NASDAQ), CHINOOK THERAPEUTICS INC (NASDAQ), VERU INC (NASDAQ), WEREWOLF THERAPEUTICS INC (NASDAQ), KALVISTA PHARMACEUTICALS INC (NASDAQ), AC IMMUNE SA (NASDAQ), VACCITECH PLC ADR EACH REPR 1 ORD SH SPON (NASDAQ), HUA MEDICINE-B (HKEx), TARSUS PHARMACEUTICALS INC (NASDAQ), ALPHA TEKNOVA INC (NASDAQ), NANOBIOTIX S A SPON ADS EACH REP 1 ORD SHS (NASDAQ), EVELO BIOSCIENCES INC (NASDAQ), TCR2 THERAPEUTICS INC (NASDAQ), CLENE INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), MIRUM PHARMACEUTICALS INC (NASDAQ), Soho Global Health Tbk. (IDX), SIGA TECHNOLOGIES INC (NASDAQ), PHARVARIS NV (NASDAQ), INOZYME PHARMA INC (NASDAQ), BOLT BIOTHERAPEUTICS INC (NASDAQ), OYSTER POINT PHARMA INC (NASDAQ), RELMADA THERAPEUTICS INC (NASDAQ), SPERO THERAPEUTICS INC (NASDAQ), ALZAMEND NEURO INC (NASDAQ), IGBB (Bursa), AMRYT PHARMA PLC (NEW) SPON ADS EACH REP 5 ORD SHS (NASDAQ), RACE ONCOLOGY LTD (ASX), STARPHARMA HOLDINGS LIMITED (ASX), PROVENTION BIO INC (NASDAQ), BEYONDSPRING INC (NASDAQ), GRITSTONE BIO INC (NASDAQ), XOMA CORP (NASDAQ), ORCHARD THERAPEUTICS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), BIOMEA FUSION INC (NASDAQ), CODIAK BIOSCIENCES INC (NASDAQ), PYC THERAPEUTICS LIMITED (ASX), ATHENEX INC (NASDAQ), AFT PHARMACEUTICALS LTD (ASX), 89BIO INC (NASDAQ), FUSION PHARMACEUTICALS INC (NASDAQ), DAWNRAYS PHARMA (HKEx), THERATECHNOLOGIES INC (NASDAQ), ANGION BIOMEDICA CORP (NASDAQ), VECTIVBIO HLDG AG (NASDAQ), DURECT CORP (NASDAQ), BSTEAD (Bursa), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), GAMIDA CELL LTD (NASDAQ), TOT BIOPHARM-B (HKEx), VERRICA PHARMACEUTICALS INC (NASDAQ), CLEARSIDE BIOMEDICAL INC (NASDAQ), IMPEL NEUROPHARMA INC (NASDAQ), SOL GEL TECHNOLOGIES LTD (NASDAQ), VINCERX PHARMA INC (NASDAQ), PHARMA (Bursa), 180 LIFE SCIENCES CORP (NASDAQ), CITIUS PHARMACEUTICALS INC (NASDAQ), PDS BIOTECHNOLOGY CORPORATION (NASDAQ), NEXIMMUNE INC (NASDAQ), ACHILLES THERAPEUTICS PLC ADS EACH REPR 1 SHARE SPON (NASDAQ), OVID THERAPEUTICS INC (NASDAQ), FULCRUM THERAPEUTICS INC (NASDAQ), FUSEN PHARM (HKEx), IMMUNIC INC (NASDAQ), MUSTANG BIO INC (NASDAQ), TYME TECHNOLOGIES INC (NASDAQ), KALA PHARMACEUTICALS INC (NASDAQ), EYEPOINT PHARMACEUTICALS INC (NASDAQ), GALERA THERAPEUTICS INC (NASDAQ), KALEIDO BIOSCIENCES INC (NASDAQ), HOOKIPA PHARMA INC (NASDAQ), HARROW HEALTH INC (NASDAQ), TFF PHARMACEUTICALS INC (NASDAQ), OSMOTICA PHARMACEUTICALS PLC (NASDAQ), XERIS PHARMACEUTICALS INC (NASDAQ), RENEO PHARMACEUTICALS INC (NASDAQ), OBSEVA SA (NASDAQ), CHECKPOINT THERAPEUTICS INC (NASDAQ), TRICIDA INC (NASDAQ), 4D PHARMA PLC SPONS ADR EACH REP 8 ORD SHS (NASDAQ), IP (SET), LANNETT CO INC (NYSE), ONCTERNAL THERAPEUTICS INC (NASDAQ), ORPHAZYME A/S SPON ADS REP 1 ORD SHS (NASDAQ), CH BIOTECH SER (HKEx), PHASEBIO PHARMACEUTICALS INC (NASDAQ), SATSUMA PHARMACEUTICALS INC (NASDAQ), MILESTONE PHARMACEUTICALS INC (NASDAQ), ANEBULO PHARMACEUTICALS INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), SCPHARMACEUTICALS INC (NASDAQ), ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ), AYALA PHARMACEUTICALS INC (NASDAQ), QILIAN INTERNATIONAL HLDG GROUP LTD (NASDAQ), LANTERN PHARMA INC (NASDAQ), IMARA INC (NASDAQ), CYCLERION THERAPEUTICS INC (NASDAQ), GENPREX INC (NASDAQ), POLYPID LTD (NASDAQ), VYNE THERAPEUTICS INC (NASDAQ), ETON PHARMACEUTICALS INC (NASDAQ), LOGICBIO THERAPEUTICS INC (NASDAQ), NOXOPHARM LTD (ASX), ODONATE THERAPEUTICS INC (NASDAQ), ZHONGZHIPHARM (HKEx), RECCE PHARMACEUTICALS LTD (ASX), IX Biopharma (SGX), AQUESTIVE THERAPEUTICS INC (NASDAQ), LIQUIDIA CORPORATION (NASDAQ), NOVAN INC (NASDAQ), ENTERA BIO LTD (NASDAQ), NEUBASE THERAPEUTICS INC (NASDAQ), EYENOVIA INC (NASDAQ), F-STAR THERAPEUTICS INC (NASDAQ), Merck Tbk. (IDX), REGENCELL BIOSCIENCE HLDGS LTD (NASDAQ), GALECTO INC (NASDAQ), PROPHASE LABS INC (NASDAQ), CRESO PHARMA LTD (ASX), MEDIWOUND LTD (NASDAQ), TEMPEST THERAPEUTICS INC (NASDAQ), AYTU BIOPHARMA INC (NASDAQ), AERPIO PHARMACEUTICALS INC (NASDAQ), AILERON THERAPEUTICS INC (NASDAQ), APTORUM GROUP LIMITED (NASDAQ), NEW RAY MEDIC (HKEx), MOLECULIN BIOTECH INC (NASDAQ), CHARMACY PHAR (HKEx), GRAYBUG VISION INC (NASDAQ), APREA THERAPEUTICS INC (NASDAQ), ELEDON PHARMACEUTICALS INC (NASDAQ), PROTARA THERAPEUTICS INC (NASDAQ), YUMANITY THERAPEUTICS INC (NASDAQ), PURPLE BIOTECH LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), LYRA THERAPEUTICS INC (NASDAQ), CORVUS PHARMACEUTICALS INC (NASDAQ), KOTRA (Bursa), ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 6 ORD SHS (NASDAQ), Phapros Tbk. (IDX), DARE BIOSCIENCE INC (NASDAQ), PAK FAH YEOW (HKEx), NC HEALTHCARE (HKEx), Hyphens Pharma (SGX), EDESA BIOTECH INC (NASDAQ), OCUPHIRE PHARMA INC (NASDAQ), AKARI THERAPEUTICS PLC SPON ADR EACH REPR 100 ORD (NASDAQ), BIOHLDG (Bursa), NOVA (Bursa), MODERN CHI MED (HKEx), UNIVERSE PHARMACEUTICALS INC (NASDAQ), INHIBIKASE THERAPEUTICS INC (NASDAQ), EXOPHARM LTD (ASX), SYNAPTOGENIX INC (NASDAQ), MANNATECH INC (NASDAQ), ALLENA PHARMACEUTICALS INC (NASDAQ), ARIDIS PHARMACEUTICAL INC (NASDAQ), BRICKELL BIOTECH INC (NASDAQ), INVION LTD (ASX), NEP INTERLONG (HKEx), ASSERTIO HOLDINGS INC (NASDAQ), BAUDAX BIO INC (NASDAQ), ACURX PHARMACEUTICALS INC (NASDAQ), WAI YUEN TONG (HKEx), VIRIOS THERAPEUTICS INC (NASDAQ), MEDLAB CLINICAL LIMITED (ASX), ADIAL PHARMACEUTICALS INC (NASDAQ), PALLA PHARMA LTD (ASX), TBG DIAGNOSTICS LTD (ASX), CNS PHARMACEUTICALS INC (NASDAQ), TELIGENT INC NEW (NASDAQ), TREVI THERAPEUTICS INC (NASDAQ), PURAPHARM (HKEx), BIONDVAX PHARMACEUTICALS SPON ADS REP 40 ORD SHS (NASDAQ), REVIVA PHARMACEUTICALS HOLDINGS INC (NASDAQ), SANAI HEALTH GP (HKEx), PANBELA THERAPEUTICS INC (NASDAQ), PAINREFORM LTD (NASDAQ), NLS PHARMACEUTICS LTD (NASDAQ), ACER THERAPEUTICS INC (NASDAQ), HOTH THERAPEUTICS INC (NASDAQ), JCT (SET), VALLON PHARMACEUTICALS INC (NASDAQ), SUNZEN (Bursa), PHARMAXIS (ASX), AVENUE THERAPEUTICS INC (NASDAQ), EXTRAWELL PHAR (HKEx), PETROS PHARMACEUTICALS INC (NASDAQ), ONCOSIL MEDICAL LIMITED (ASX), TALI DIGITAL LIMITED (ASX), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), IMMURON LIMITED (ASX), ACRUX (ASX), TITAN PHARMACEUTICAL INC (NASDAQ), VIRPAX PHARMA INC (NASDAQ), CHINA SXT PHARMACEUTICALS INC (NASDAQ), ISLAND PHARMACEUTICALS LTD (ASX), SINOLIFE UTD (HKEx), SUDA PHARMACEUTICALS LTD (ASX), PASHUN INT'L (HKEx), FIJI KAVA LTD (ASX), CELLMID LIMITED (ASX), FARMAFORCE LTD (ASX), Pharmesis Intl (SGX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days -+11.060
+10.93 %
10 Days --8.730
-7.22 %
20 Days -+28.390
+33.86 %
Medium Term Return 3 Months -+88.440
+371.60 %
6 Months -+101.660
+960.87 %
1 Year -+106.370
+1812.10 %
Annualised Return Annualised --
+1812.10 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 4.140 - 132.000 Change From 1 Year Low +108.100 % Change From 1 Year Low (%) +2611.11
Change From 1 Year High -19.760 % Change From 1 Year High (%) -14.97
2 Years Range 2.418 - 132.000 Change From 2 Years Low +109.822 % Change From 2 Years Low (%) +4541.85
Change From 2 Years High -19.760 % Change From 2 Years High (%) -14.97
5 Years Range 2.418 - 132.000 Change From 5 Years Low +109.822 % Change From 5 Years Low (%) +4541.85
Change From 5 Years High -19.760 % Change From 5 Years High (%) -14.97
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Annovis Bio, Inc. is a clinical stage drug platform company, which develops drugs to treat neurodegeneration. The firm compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. It is also develops ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Berwyn, PA.

Historical Price Data

Date Open High Low Close Volume VWAP
27 Jul 2021 114.000 117.640 105.030 112.240 542,161 -
26 Jul 2021 122.170 124.880 110.110 114.510 529,591 -
23 Jul 2021 120.000 132.000 112.780 119.000 1,014,513 -
22 Jul 2021 113.790 114.148 105.644 107.110 384,084 -
21 Jul 2021 103.240 111.852 100.180 111.000 551,194 -
20 Jul 2021 102.580 104.950 95.000 101.180 340,531 -
19 Jul 2021 98.000 106.280 93.000 100.500 415,862 -
16 Jul 2021 103.270 109.690 100.549 103.990 360,384 -
15 Jul 2021 114.710 115.700 99.000 100.550 562,604 -
14 Jul 2021 121.110 122.950 112.650 114.780 447,846 -
13 Jul 2021 119.000 125.550 115.900 120.970 738,337 -
12 Jul 2021 109.000 121.340 109.000 117.260 783,725 -
09 Jul 2021 113.000 125.950 98.090 104.820 1,445,251 -
08 Jul 2021 95.680 111.050 93.005 110.880 1,012,239 -
07 Jul 2021 105.500 105.500 96.350 102.850 747,592 -
06 Jul 2021 95.880 107.910 94.500 102.980 944,146 -
02 Jul 2021 91.110 98.649 87.580 97.000 719,803 -
01 Jul 2021 87.790 90.871 84.320 88.860 422,925 -
30 Jun 2021 83.000 86.790 82.010 85.580 345,284 -
29 Jun 2021 87.500 87.990 82.450 83.850 419,901 -
28 Jun 2021 80.990 87.830 79.880 87.500 607,036 -
25 Jun 2021 81.670 83.870 79.000 81.620 426,574 -
Summary
Current 2 Weeks
(14 Jul 2021 to 27 Jul 2021)
121.110 132.000 93.000 112.240 5,148,770 -
Previous 2 Weeks
(29 Jun 2021 to 13 Jul 2021)
87.500 132.000 82.450 120.970 7,579,203 -
4 Weeks from
(01 Jun 2021 to 28 Jun 2021)
46.610 132.000 44.250 87.500 20,499,168 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.